January 21, 2026

Company Name:	HEALIOS K.K.
Representative:	Hardy TS Kagimoto, Chairman & CEO (TSE Growth Code: 4593)
Contact:	Richard Kincaid, Executive Officer CFO (TEL: 03-4590-8009)

Announcement of Letter of Intent with Alfresa Corporation regarding the Sale and Purchase of Somatic Stem Cell Culture Supernatant

HEALIOS K.K. ("Healios") today announces that Healios and Alfresa Corporation ("Alfresa" https://www.alfresa.co.jp/en/) have entered into a letter of intent ("LOI") for the continuous sale and purchase of human (allogeneic) bone marrow-derived somatic stem cell culture supernatant manufactured by Healios (product name: HLSI071, the "Culture Supernatant").

1. Outline of the LOI

Healios is engaged in the development, manufacturing, and commercialization of innovative therapies and products in the field of regenerative medicine. As part of this initiative, Healios is promoting the research, development, and manufacture of products based on somatic stem cell culture supernatant.

The purpose of the LOI with Alfresa, a leading pharmaceutical wholesaler in Japan, is to discuss the establishment of a framework that enables stable and efficient distribution of Healios' products, thereby allowing for the timely delivery of the Culture Supernatant to customers.

As previously announced in the "Basic Business Alliance Agreement and Bond Purchase Agreement with Alfresa Corporation" dated June 5, 2024, Healios has already entered into a basic business alliance agreement with Alfresa concerning the distribution and sales of Healios' products. The LOI is intended to further develop this existing business alliance. Based on the LOI, Healios and Alfresa will continue discussions regarding the detailed terms of the transactions, including specific arrangements for product distribution and supply systems. Healios expects to promote the provision of its products to customers.

Target Product:

Human (allogeneic) bone marrow-derived somatic stem cell culture supernatant (HLSI071)

In addition, as announced in the "Announcement of Letter of Intent with Cell Resources for the Production of Culture Supernatant" dated January 16, 2025, Healios had been discussing a potential manufacturing-related business alliance with Cell Resources Co., Ltd ("Cell Resources" 100% invested by Alfresa Holdings Corporation). However, in light of the execution of the LOI with Alfresa and the commencement of operations at Healios' own manufacturing facility for culture supernatant, Healios has decided to conclude its discussions with Cell Resources.

2. Future Outlook

This matter has no impact on our consolidated financial results of the fiscal year ending December 31, 2026 at this time. We will promptly announce any matters that should be disclosed in the future.

About Alfresa:
Since its establishment in 2004, Alfresa has contributed to healthcare by supplying pharmaceuticals, medical devices, diagnostic reagents, nutritional products, and other healthcare-related products sourced from approximately 1,000 manufacturers worldwide to hospitals, clinics, and pharmacies. Leveraging a nationwide network of approximately 170 locations, Alfresa provides a range of services and solutions aimed at improving operational efficiency and the quality of healthcare in local communities.
https://www.alfresa.co.jp/en/

About Healios:
HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells.

In the somatic stem cell field, Healios is developing invimestrocel (HLCM051), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. Invimestrocel has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance invimestrocel on a global basis for ischemic stroke, ARDS, and trauma.

In the iPSC regenerative medicine field, Healios is developing HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-editing. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human testing in collaboration with Akatsuki Therapeutics. The company has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need.

Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593). https://www.healios.co.jp/en

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp